Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines

Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv119–iv142.
Authors: J. Haanen, F. Carbonnel, C. Robert, K. Kerr, S. Peters, J. Larkin and K. Jordan

Immunotherapy is an essential component of cancer care and expands the treatment possibilities for patients. Immune checkpoint inhibitors are among the most promising drugs but are associated with toxicities. The most frequently occurring ones affect skin, colon, endocrine organs, liver and lungs. Others are very infrequent but may be very serious, even lethal, such as neurological disorders and myocarditis. These new ESMO Clinical Practice Guidelines provide an overview of the main immune-related adverse events and include recommendations for their management.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings